These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 17912140)

  • 1. Use of weekly alendronate to treat osteoporosis in boys with muscular dystrophy.
    Apkon S; Coll J
    Am J Phys Med Rehabil; 2008 Feb; 87(2):139-43. PubMed ID: 17912140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
    McComsey GA; Kendall MA; Tebas P; Swindells S; Hogg E; Alston-Smith B; Suckow C; Gopalakrishnan G; Benson C; Wohl DA
    AIDS; 2007 Nov; 21(18):2473-82. PubMed ID: 18025884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy.
    Tian C; Wong BL; Hornung L; Khoury JC; Rybalsky I; Shellenbarger KC; Rutter MM
    Neuromuscul Disord; 2020 Jul; 30(7):599-610. PubMed ID: 32680651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increase in bone mass after correction of vitamin D insufficiency in bisphosphonate-treated patients.
    Geller JL; Hu B; Reed S; Mirocha J; Adams JS
    Endocr Pract; 2008 Apr; 14(3):293-7. PubMed ID: 18463035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized controlled trial of alendronate in airways disease and low bone mineral density.
    Smith BJ; Laslett LL; Pile KD; Phillips PJ; Phillipov G; Evans SM; Esterman AJ; Berry JG
    Chron Respir Dis; 2004; 1(3):131-7. PubMed ID: 16281654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-week trial (ANRS 120).
    Rozenberg S; Lanoy E; Bentata M; Viard JP; Valantin MA; Missy P; Darasteanu I; Roux C; Kolta S; Costagliola D;
    AIDS Res Hum Retroviruses; 2012 Sep; 28(9):972-80. PubMed ID: 22353022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the effects of alendronate and alfacalcidol on bone mineral density around the femoral implant and in the lumbar spine after total hip arthroplasty.
    Iwamoto N; Inaba Y; Kobayashi N; Ishida T; Yukizawa Y; Saito T
    J Bone Joint Surg Am; 2011 Jul; 93(13):1203-9. PubMed ID: 21776573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis.
    Roux C; Binkley N; Boonen S; Kiel DP; Ralston SH; Reginster JY; Pong A; Rosenberg E; Santora A;
    Calcif Tissue Int; 2014 Feb; 94(2):153-7. PubMed ID: 23912950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
    Skordis N; Ioannou YS; Kyriakou A; Savva SC; Efstathiou E; Savvides I; Christou S
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():144-8. PubMed ID: 19337169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone density and alendronate effects in Duchenne muscular dystrophy patients.
    Houston C; Mathews K; Shibli-Rahhal A
    Muscle Nerve; 2014 Apr; 49(4):506-11. PubMed ID: 23835890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
    Planas J; Trilla E; Raventós C; Cecchini L; Orsola A; Salvador C; Placer J; Encabo G; Morote J
    BJU Int; 2009 Dec; 104(11):1637-40. PubMed ID: 19549260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study.
    Millonig G; Graziadei IW; Eichler D; Pfeiffer KP; Finkenstedt G; Muehllechner P; Koenigsrainer A; Margreiter R; Vogel W
    Liver Transpl; 2005 Aug; 11(8):960-6. PubMed ID: 16035083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
    J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alendronate for steroid-induced osteopenia in children with acute lymphoblastic leukaemia or non-Hodgkin's lymphoma: results of a pilot study.
    Wiernikowski JT; Barr RD; Webber C; Guo CY; Wright M; Atkinson SA
    J Oncol Pharm Pract; 2005 Jun; 11(2):51-6. PubMed ID: 16460605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
    Stoch SA; Saag KG; Greenwald M; Sebba AI; Cohen S; Verbruggen N; Giezek H; West J; Schnitzer TJ
    J Rheumatol; 2009 Aug; 36(8):1705-14. PubMed ID: 19487264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
    Orwoll ES; Miller PD; Adachi JD; Brown J; Adler RA; Kendler D; Bucci-Rechtweg C; Readie A; Mesenbrink P; Weinstein RS
    J Bone Miner Res; 2010 Oct; 25(10):2239-50. PubMed ID: 20499357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategy of aggressive steroid weaning and routine alendronate therapy to reduce bone loss after cardiac transplantation.
    Yong G; Hayes H; O'Driscoll G
    Transplant Proc; 2007 Dec; 39(10):3340-3. PubMed ID: 18089383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined therapies in osteoporosis: bisphosphonates and vitamin D-hormone analogs.
    Schacht E; Dukas L; Richy F
    J Musculoskelet Neuronal Interact; 2007; 7(2):174-84. PubMed ID: 17627088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium.
    Sambrook PN; Kotowicz M; Nash P; Styles CB; Naganathan V; Henderson-Briffa KN; Eisman JA; Nicholson GC
    J Bone Miner Res; 2003 May; 18(5):919-24. PubMed ID: 12733733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring alendronate and estradiol therapy with quantitative ultrasound and bone mineral density.
    Ingle BM; Machado AB; Pereda CA; Eastell R
    J Clin Densitom; 2005; 8(3):278-86. PubMed ID: 16055957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.